3-甲氧基苄肼 | 85293-12-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-甲氧基苄肼
• 中文别名: 1-(3-甲氧基苄基)肼
• 英文名称: (3-methoxy-benzyl)-hydrazine
• 英文别名: (3-Methoxy-benzyl)-hydrazin；3-methoxybenzylhydrazine；(3-Methoxybenzyl)hydrazine；(3-methoxyphenyl)methylhydrazine
• CAS: 85293-12-5
• 化学式: C₈H₁₂N₂O
• mdl: MFCD06245507
• 分子量: 152.196
• InChiKey: UPLGQRHDYAHDRC-UHFFFAOYSA-N

物化性质

• 熔点：
  116-118°C
• 沸点：
  311℃
• 密度：
  1.069
• 闪点：
  142℃

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2928000090

反应信息

• 作为反应物：
  描述：

  3-甲氧基苄肼 、 丙烯腈 生成 1-(3'-methoxybenzyl)-3-amino-2-pyrazoline
  参考文献：
  名称：

  HAVIV, F.;DE, NET, R. W.;BOULANGER, W. A.

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-1-(3-methoxybenzyl)-2-(3-methoxybenzylidene)hydrazine 在 盐酸 作用下， 生成 3-甲氧基苄肼
  参考文献：
  名称：

  Curtius, Journal fur praktische Chemie (Leipzig 1954), 1912, vol. <2> 85, p. 418

  摘要：

  DOI：

文献信息

• ADENOSINE A2A RECEPTOR ANTAGONISTS
  申请人：Clasby Martin C.

  公开号：US20080255156A1

  公开（公告）日：2008-10-16

  Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein: X 1 and X 2 are 1-3 substituents independently selected from the group consisting of H, alkyl, halo, —CF 3 , —OCF 3 , alkoxy, —OH and —CN; n is 0, 1 or 2; and R and R 1 are H or alkyl; also disclosed is the use of the compounds in the treatment of CNS diseases such as Parkinson's disease, alone or in combination with other agents for treating CNS diseases, pharmaceutical compositions comprising them and kits comprising the components of the combinations.

  具有结构式I或其药用可接受盐的化合物，其中：X1和X2分别选自H、烷基、卤、—CF3、—OCF3、烷氧基、—OH和—CN组成的1-3个取代基；n为0、1或2；R和R1为H或烷基；还公开了该化合物在治疗中枢神经系统疾病如帕金森病中的用途，单独或与其他治疗中枢神经系统疾病的药剂联合使用，包括它们的药物组合物和包含该组合物成分的工具包。
• 4,5-dihydro-&lsqb;1H&rsqb;-benz&lsqb;g&rsqb;indazole-3-carboxylic acid derivatives
  申请人：Teikoku Hormone Mfg. Co., Ltd.

  公开号：US06291485B1

  公开（公告）日：2001-09-18

  4,5-Dihydro-[1H]-benz[g]indazole-3-carboxylic acid derivatives represented by the following formula, or their salts, have excellent antagonism to endothelin receptors and are useful as preventives or remedies for diseases such as hypertension, angina pectoris, myocardial infarction, brain infarction, cerebrovascular contraction, renal insufficiency, hepatic dysfunction, arteriosclerosis and post-PTCA restenosis. wherein Ar represents an optionally substituted aryl group, and R1 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group or an optionally substituted heterocyclic group.

  以下公式所代表的4,5-二氢-[1H]-苯[g]吲唑-3-羧酸衍生物，或其盐，对内皮素受体具有出色的拮抗作用，并可用作预防或治疗高血压、心绞痛、心肌梗死、脑梗死、脑血管收缩、肾功能不全、肝功能障碍、动脉硬化和PTCA术后再狭窄等疾病的药物。其中Ar代表可选择取代的芳基，R1代表氢原子、可选择取代的较低烷基、可选择取代的芳基、可选择取代的环烷基或可选择取代的杂环基。
• Method for treating inflammatory conditions
  申请人：Abbott Laboratories

  公开号：US04370339A1

  公开（公告）日：1983-01-25

  A method for treating an inflammatory condition in a mammalian patient by administering an effective amount of a 1-aralkyl-3-amino-2-pyrazoline compound having the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein: m and n are integers ranging from 0 to 6, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5, which can be the same or different, are hydrogen or lower alkyl, X.sub.1, X.sub.2, X.sub.3, X.sub.4, and X.sub.5, which can be the same or different, are hydrogen, halogen, alkyl, cycloalkyl, alkoxy, alkanoyloxy, phenyl, phenoxy, benzyloxy, haloalkyl, mercaptoalkyl, amino, alkylamine, hydroxyl, nitro, and nitrile, each of X.sub.1 -X.sub.5, when they contain carbon, having not more than 6 carbon atoms. The compounds used in the method have unexpectedly low toxicity.

  通过向哺乳动物患者施用有效量的具有以下结构式的1-芳基-3-氨基-2-吡唑啉化合物或其药学上可接受的酸加合物来治疗炎症状况，其中：m和n是从0到6的整数，R1，R2，R3，R4和R5可以相同也可以不同，是氢或较低的烷基，X1，X2，X3，X4和X5可以相同也可以不同，是氢、卤素、烷基、环烷基、烷氧基、烷酰氧基、苯基、苯氧基、苄氧基、卤代烷基、巯基烷基、氨基、烷基胺、羟基、硝基和腈基，其中X1-X5中的每一个，当它们包含碳时，碳原子数不超过6。该方法中使用的化合物具有意外的低毒性。
• Synthesis, Characterization and Antimicrobial Evaluation of Amino acid Derivatives of 1,3,4-Oxadiazole
  作者：Yudhishthir Vaishnav、Sangeeta Rajpurohit、Kamalkant Vyas

  DOI：10.13005/ojc/390422

  日期：2023.8.30

  Several novel 1,3,4-oxadiazole compounds were synthesized for this investigation. NMR and IR spectrum analysis as well as carbon, hydrogen, and nitrogen studies were used to characterize these novel synthesized compounds. Antibacterial and antifungal tests were conducted on all of the newly synthesized compounds. Staphylococcus aureus and Bacillus subtilis, both Gram +ve bacteria, and Escherichia coli

  本研究合成了几种新型 1,3,4-恶二唑化合物。核磁共振和红外光谱分析以及碳、氢和氮研究被用来表征这些新型合成化合物。对所有新合成的化合物进行了抗菌和抗真菌测试。金黄色葡萄球菌和枯草芽孢杆菌（均为革兰氏阳性细菌）以及大肠杆菌和铜绿假单胞菌（均为革兰氏阴性细菌）被用于抗菌研究。使用黑曲霉和白色念珠菌来测试抗真菌治疗的功效。环丙沙星和氟康唑分别用作抗菌和抗真菌研究的参考药物。所有物质的抑制作用从轻微到强烈不等。筛选结果表明，其中几种化合物比标准药物具有更强的抗菌和抗真菌特性。
• 4,5-DIHYDRO- 1H]-BENZ g]INDAZOLE-3-CARBOXYLIC ACID DERIVATIVES
  申请人：TEIKOKU HORMONE MFG. CO., LTD.

  公开号：EP1002797A1

  公开（公告）日：2000-05-24

  4,5-Dihydro-[1H]-benz[g]indazole-3-carboxylic acid derivatives represented by the following formula, or their salts, have excellent antagonism to endothelin receptors and are useful as preventives or remedies for diseases such as hypertension, angina pectoris, myocardial infarction, brain infarction, cerebrovascular contraction, renal insufficiency, hepatic dysfunction, arteriosclerosis and post-PTCA restenosis. wherein Ar represents an optionally substituted aryl group, and R1 represents a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted aryl group, an optionally substituted cycloalkyl group or an optionally substituted heterocyclic group.

  下式所代表的 4,5-二氢-[1H]-苯并[g]吲唑-3-羧酸衍生物或其盐类对内皮素受体具有极好的拮抗作用，可作为高血压、心绞痛、心肌梗塞、脑梗塞、脑血管收缩、肾功能不全、肝功能障碍、动脉硬化和 PTCA 术后再狭窄等疾病的预防或治疗药物。 其中 Ar 代表任选取代的芳基，R1 代表氢原子、任选取代的低级烷基、任选取代的芳基、任选取代的环烷基或任选取代的杂环基。